Mon, August 28 – 10 Stories of The Day!
28 Aug, 2017 | 00:14h | UTC
#ESCCongress – Highlights from the European Society of Cardiology Congress 2017
1 – 2017 ESC/EACTS Guidelines for the management of valvular heart disease (free) (RT @rafavidalperez see Tweet)
Commentary: European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts – TCTMD (free)
See also: #ESCCongress Slides (free PPT file)
2 – 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) (free) (RT @rafavidalperez see Tweet)
Commentary: ESC Updates Guidelines for Treating STEMI Patients – TCTMD (free)
See also: #ESCCongress Slides (free PPT file)
3 – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries (free) (RT @rafavidalperez see Tweet)
See also: #ESCCongress Slides (free PPT file)
4 – 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS (free) (RT @rafavidalperez see Tweet)
See also: #ESCCongress Slides (free PPT file)
Editorial by Dr. Eugene Braunwald: An Important Step for Thrombocardiology (free)
Commentaries: Cardiovascular Outcomes for People Using Anticoagulation Strategies – COMPASS – American College of Cardiology, Latest in Cardiology (free) AND COMPASS: Does Rivaroxaban Plus Aspirin Improve CV Outcomes in Patients With Stable Atherosclerotic Vascular Disease or PAD? – ACC News Story (free) AND Rivaroxaban, Aspirin, or Both in Stable Coronary Disease – Physician’s First Watch (free)
The primary outcome (composite of cardiovascular death, stroke, or myocardial infarction) occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (4.1% vs. 5.4% / Absolute risk difference = 1.3% / NNT = 76), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (3.1% vs. 1.9% / Absolute risk difference = 1.2 / NNH = 83).
Commentaries: Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention – RE-DUAL PCI – American College of Cardiology, Latest in Cardiology (free) Dual Antithrombotic Therapy Is Safe for Patients with AF and a New Stent – Physician’s First Watch (free) AND When two is better than three: Dual antithrombotic therapy cuts bleeding risk – Brigham and Women’s Hospital, via ScienceDaily (free)
“In summary, several lines of evidence now suggest that it is safe to treat atrial fibrillation patients who undergo coronary revascularization with anticoagulation (warfarin studied in WOEST, rivaroxaban studied in PIONEER AF-PCI, dabigatran studied in RE-DUAL PCI) and clopidogrel monotherapy” (from American College of Cardiology, Latest in Cardiology).
Editorial: Targeting Inflammation in Coronary Artery Disease (free)
Commentaries: Anti-Inflammatory Therapy for Atherosclerotic Disease: A Step Closer? – Physician’s First Watch (free) AND CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events – TCTMD (free) AND CANTOS Validates Role Of Inflammation In Heart Disease – Cardiobrief (free)
“This widely anticipated study delivered some modestly positive results (fewer nonfatal MIs), some worrisome results (increased fatal infections), and some unexpected results (fewer cancer deaths)” (from Physician’s First Watch).
Commentary: CASTLE-AF: Catheter Ablation vs. Conventional Therapy For Patients With AFib and LV Dysfunction – American College of Cardiology, Latest in Cardiology (free)
The study has not been published yet, but the results suggest that patients with symptomatic paroxysmal or persistent AF and heart failure with ejection fraction less than 35% may have a better outcome with catheter ablation.
Commentaries: What Do Implanted Cardiac Monitors Reveal About Atrial Fibrillation? – JAMA Cardiology (free) AND REVEAL AF: Incidence of AFib Could Be Substantial in Older Patients With Stroke Risk Factors – American College of Cardiology, Latest in Cardiology (free) AND Detection of Undiagnosed AF Using Insertable Cardiac Monitors – American College of Cardiology, Latest in Cardiology (free)
Implanted Cardiac Monitors showed the incidence of intermittent atrial fibrillation is extremely common among older individuals with stroke risk factors, but the clinical significance of these findings (do they need to be anticoagulated??) remains to be determined by further trials.
“Previous long-term monitoring studies have suggested that patients with short episodes of subclinical AF have a lower risk of stroke compared with traditional clinical AF, which raises important questions about the risk-benefit ratio of anticoagulation in this setting” (from Latest in Cardiology).
10 – CI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease – Journal of The American College of Cardiology (link to abstract – $ for full-text)
Commentaries: Patients With Type 1 Diabetes and Multivessel Disease Have Greater Benefit From CABG Than PCI – American College of Cardiology, Latest in Cardiology (free) AND Revascularization in Patients With Type 1 Diabetes – American College of Cardiology, Latest in Cardiology (free) AND CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease – TCTMD (free)
“The observational findings support existing recommendations favoring surgical revascularization in patients with diabetes” (from TCTMD).